Welcome to our dedicated page for Opko Health news (Ticker: OPK), a resource for investors and traders seeking the latest updates and insights on Opko Health stock.
OPKO Health reports developments across a multinational biopharmaceutical and diagnostics business. Recurring updates cover operating results, financial guidance, BioReference laboratory testing services and digital access through BioReference Direct, and RAYALDEE commercialization through EirGen Pharma in Greater China.
The company also reports research collaborations and clinical development from ModeX Therapeutics, including its MSTAR multispecific antibody platform, MDX2301 for COVID-19 prevention, and MDX2003, a tetraspecific T-cell engager for B-cell lymphomas. News also includes pharmaceutical partnerships, diagnostic-service changes, investor presentations, and business updates tied to OPKO's pharmaceutical and diagnostics segments.
BioReference Laboratories, part of OPKO Health (NASDAQ: OPK), has received an Indefinite Delivery Indefinite Quantity (IDIQ) contract from the CDC for Commercial Surge Capacity Testing amid the COVID-19 pandemic. The contract, effective from July 20 to November 19, 2020, focuses on antibody testing to determine COVID-19 seroprevalence and will involve collaboration with the CDC for data analysis. This partnership emphasizes the need for public-private collaboration in effectively responding to the COVID-19 crisis.
BioReference Laboratories, an OPKO Health company (NASDAQ: OPK), has been selected to conduct COVID-19 testing for Major League Soccer (MLS) players and staff during the MLS is Back Tournament in Orlando, starting July 9, 2020. This partnership involves PCR and antibody testing to ensure a safe environment for the league's return. Additionally, BioReference is providing community antibody testing at the Orlando Vineland Premium Outlets, which commenced on July 6, 2020. This initiative underscores BioReference's role in supporting public health amid the pandemic.
BioReference Laboratories, part of OPKO Health, reported the results of COVID-19 testing for nursing home staff in New York State. Following a state mandate, PCR and antibody tests were conducted on approximately 3,500 employees. Notably, 29% tested positive for antibodies, suggesting significant prior exposure among the estimated 140,000 nursing home staff. Active infection rates were much lower at 2.9%. The findings indicate that widespread testing likely helped prevent further virus spread to vulnerable residents, highlighting BioReference's commitment to combating COVID-19.
OPKO Health announced positive results from a Phase 3 clinical trial for somatrogon, a treatment for pediatric growth hormone deficiency, in Japan. The study met its primary and secondary objectives, demonstrating that somatrogon is comparably effective and safe when administered weekly versus the daily injection of GENOTROPIN. The somatrogon group showed a greater annual height velocity (9.65 cm/year) compared to GENOTROPIN (7.87 cm/year). With most adverse events being mild to moderate, the trial results represent a significant milestone for OPKO and may improve patient adherence and quality of life.
OPKO Health (NASDAQ: OPK) will participate in the Jefferies Virtual Healthcare Conference from June 2-4, 2020. Management is set to host one-on-one meetings with investors and will present on June 3 at 3:00 p.m. Eastern time. The presentation will be available via a live webcast and can be replayed afterward in the Investors section of OPKO's website.
OPKO is a biopharmaceutical and diagnostics company focused on leveraging its proprietary technologies to capture opportunities in rapidly growing markets. More information can be found at www.opko.com.
Summary not available.